Curis, Inc. · NASDAQ:CRIS
Curis — Investor Presentation (February 2006)
24 slides from Curis's investor presentation, February 2006
Slide 1: Curis, Inc. (NASDAQ: CRIS) February 2006
Curis, Inc. (NASDAQ: CRIS) February 2006 ©2006 Curis Inc.
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains statements about Curis’s future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially
Slide 3: Presentation Outline
Presentation Outline Business Model Collaborations and Product Candidates Patents/Financials 3 ©2006 Curis Inc.
Slide 4: Curis Business Strategy
Curis Business Strategy Research expertise allows Curis to sign high-value agreements with top- tier biotech and pharma companies for late-stage preclinical candidates Diverse collaboration structures allow for calculated risk assumption and retained technology rights • Curis is co-developing a
Slide 5: Curis Collaborative / Licensed Programs
Curis Collaborative / Licensed Programs Collaborator Technology Compound Primary Indication Hh pathway Small molecule Basal cell carcinoma antagonist (topical formulation) Hh pathway Sm. mol. Antag. Other solid tumors and antibodies (systemic formulation) Hh pathway Small molecule Stroke and other a
Slide 6: Curis Model: Current
Curis Model: Current Disco Target Med Preclinical IND Clinical Phases Products Valid HTS Chem Early Mid Late very I II III BCC Co-Dev’t PYY Obesity BMP-7 Kidney Hh Oncology 10 FTEs Hh Neurology 8 FTEs Hair Re- Growth 2 FTEs (Co-Dev’t Option) Cardio 12 FTEs (Genentech Discovery) Stem Cell SMA 8 FTEs
Slide 7: Curis Proprietary Programs
Curis Proprietary Programs Curis Program Technology Compound Primary Indication Discovery Small Spinal Muscular Screening Molecules Atrophy (1) Hh pathway Nucleic Acid Cardiovascular (local delivery) Discovery Small Not disclosed Screening Molecules Discovery Small BMP-7 Agonists (2) Screening Molec
Slide 8: Presentation Outline
Presentation Outline Business Model Collaborations and Product Candidates Patents/Financials/Summary 8 ©2006 Curis Inc.
Slide 9: Hedgehog Pathway Antagonist Program
Hedgehog Pathway Antagonist Program Basal Cell Carcinoma and other Solid Tumor Cancers Collaboration with 9 ©2005 ©2006 Curis Inc.
Slide 10: Genentech Hh Antagonist Collaboration
Genentech Hh Antagonist Collaboration Established: June 2003 Deal structure: $8.5 million up-front payment, development milestones, product royalties, minimum two years R&D support, BCC co- development option in U.S. Primary indications: Topical treatment for basal cell carcinoma (co-development pro
Slide 11: Phase I Trial for Basal Cell Carcinoma
Phase I Trial for Basal Cell Carcinoma The Phase I study is a double-blind, randomized, placebo-controlled study that will enroll approximately 60 patients The primary outcomes measured in this trial will be the safety and tolerability of a multi-dose regimen of the Hedgehog antagonist Curis a
Slide 12: Phase I Trial for BCC Updated
Phase I Trial for BCC Updated The dose-escalation segment of the trial has recently completed Preliminary data from the dose-escalation segment suggest that the drug candidate appears to be safe and well tolerated and, while some clinical activity was observed, it was less than anticipated Enr
Slide 13: Phase I Trial for BCC Options
Phase I Trial for BCC Options If the current drug candidate does not advance into Phase II clinical trials, there are several possible development scenarios including, but not limited to, the following: Extend the duration of the treatment regimen of the existing drug candidate (as formulated) R
Slide 14: Genentech Hedgehog Antagonist Collaboration: Anticipated Milestones
Genentech Hedgehog Antagonist Collaboration: Anticipated Milestones Selection of lead drug October 2005 completed development candidate for other solid tumors First IND filing Curis estimates second for other solid tumors half of 2006 (cash milestone payment) Data from BCC First half of 2006 Phase I
Slide 15: Hair Growth Regulation
Hair Growth Regulation (Hedgehog Agonist Technologies) Collaboration with 15 ©2005 ©2006 Curis Curis Inc. Inc.
Slide 16: Small Molecule Hedgehog Agonist Promotes Hair Growth
Small Molecule Hedgehog Agonist Promotes Hair Growth Vehicle Treated Agonist Treated One dose, topical application, day 13 after treatment 16 Source: internal Curis research ©2006 Curis Inc.
Slide 17: Hair Growth R&D Agreement with P&G
Hair Growth R&D Agreement with P&G Curis could receive more than $100 million in milestone payments, in addition to royalties and research support. P&G receives a worldwide exclusive license to Curis’ Hedgehog agonist technology for dermatological indications. At the time of IND filing, Curis
Slide 18: Curis Proprietary Programs
Curis Proprietary Programs Curis Program Technology Compound Primary Indication Discovery Small Spinal Muscular Screening Molecules Atrophy (1) Hh pathway Nucleic Acid Cardiovascular (local delivery) Discovery Small Not disclosed Screening Molecules Discovery Small BMP-7 Agonists (2) Screening Molec
Slide 19: Presentation Outline
Presentation Outline Business Model Collaborations and Product Candidates Patents/Financials 19 ©2006 Curis Inc.
Slide 20: Strong Intellectual Property Position
Strong Intellectual Property Position Approximately 200 US patents issued or allowed and over 100 pending in U.S. Approximately 300 foreign patents issued or allowed and 350 foreign patents pending Compositions of matter covering signaling proteins, receptors, antibodies, small molecule agonists
Slide 21: Financial Data
Financial Data September 30, 2005 (amounts in 000’s except per share data) Cash, cash equivalents, investments $ 42,800 Accounts receivable $ 2,000 Convertible debt $ 2,500 Other debt $ 2,800 Shareholders’ equity $ 41,500 Basic shares outstanding 48,300 Fully diluted shares outstanding 60,100 YTD lo
Slide 22: 2005 Achievements
2005 Achievements Signed collaboration with P&G for hair growth Start of Phase I trial in BCC with Genentech Co-development deal signed with Genentech for BCC Second development deal signed with Genentech Extended funding granted from Genentech for solid tumor program Development milesto
Slide 23: Upcoming Milestones
Upcoming Milestones Genentech Collaboration - Cancer Data from BCC Phase I trial 1H 2006 First IND filing for other solid tumors 2H 2006 Wyeth Collaboration – Stroke Possible selection of lead candidate 2006-2007 P&G Collaboration – Hair Growth Preclinical milestones ($2.8M) 2006+ CV, SMA and other
Slide 24: Curis, Inc. (NASDAQ: CRIS) February 2006
Curis, Inc. (NASDAQ: CRIS) February 2006 ©2006 Curis Inc.